Integra LifeSciences (NASDAQ: IART) CEO RSU vesting, tax sale filed

Rhea-AI Filing Summary

Integra LifeSciences Holdings Corp President & CEO Mojdeh Poul reported routine equity compensation activity. On January 6, 2026, 848 and 542 shares of common stock were acquired at $0 per share upon the vesting and settlement of corresponding restricted stock units.

On the same date, 848 and 542 common shares were disposed of at $13.13 per share in transactions coded "F", reflecting shares withheld or sold to cover taxes. Following these transactions, the report shows no directly held common stock, while Ms. Poul continues to hold restricted stock unit awards, with post-transaction amounts reported as 102,840 and 102,298 units in two separate grants. A footnote explains that these awards vest in three equal annual installments starting January 6, 2026 and are scheduled for deferred delivery after her separation from service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poul Mojdeh

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M		848	A	$0	848	D
Common Stock	01/06/2026		M		542	A	$0	1,390	D
Common Stock	01/06/2026		F		848	D	$13.13	542	D
Common Stock	01/06/2026		F		542	D	$13.13	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	01/06/2026		M			848	(1)	(1)	Common Stock	848	$0	102,840	D
Restricted Stock Units	$0(1)	01/06/2026		M			542	(1)	(1)	Common Stock	542	$0	102,298	D

Explanation of Responses:

1. The award was a restricted stock unit award which vests in three annual equal installments on the first, second and third anniversaries of the grant date of 1/6/2025 of which the first installment vested on 1/6/2026 and which shall be delivered to Ms. Poul within 30 days following the first business day that occurs immediately following the six-month period after the date of her separation of service as deferred compensation.

Remarks:

	/s/ Lesha Shinn; Attorney-in-Fact for Mojdeh Poul	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IART CEO Mojdeh Poul report on January 6, 2026?

On January 6, 2026, President & CEO Mojdeh Poul reported the vesting of restricted stock units into 848 and 542 shares of Integra LifeSciences common stock, followed by corresponding share dispositions to cover taxes.

How many Integra LifeSciences (IART) shares were acquired and disposed of in this Form 4?

Ms. Poul acquired 848 and 542 common shares at $0 per share through RSU settlement and, on the same day, disposed of 848 and 542 common shares at $13.13 per share in tax-related transactions coded "F".

What restricted stock unit holdings does IART CEO Mojdeh Poul report after these transactions?

After the January 6, 2026 transactions, the filing reports Ms. Poul beneficially owns restricted stock units in two awards, with 102,840 units and 102,298 units shown as post-transaction amounts.

What is the vesting schedule of the Integra LifeSciences restricted stock unit award described in the footnote?

The footnote states the award vests in three equal annual installments on the first, second, and third anniversaries of the January 6, 2025 grant date, with the first installment vesting on January 6, 2026.

When will the vested RSUs for IART CEO Mojdeh Poul be delivered as common stock?

According to the footnote, shares from the restricted stock unit award are to be delivered to Ms. Poul within 30 days following the first business day that occurs immediately after the six-month period following the date of her separation of service, as deferred compensation.

Does this IART Form 4 indicate direct or indirect ownership for the reported securities?

The filing lists all reported common stock and restricted stock unit positions with an ownership form of Direct (D) and does not include any separate nature-of-ownership description.